idarubicin
idarubicin: 7 clinical trials tracked.
idarubicin evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about idarubicin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 3 study sponsors
Clinical Trials (7)
Anthracycline-based Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1: a Prospective, Randomized, Controlled Phase III Clinical Trial
Primary endpoint: overall survival
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Primary endpoint: Rate of dose limiting toxicities (DLTs) per dose level
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Primary endpoint: Incidence of dose-limiting toxicities during cycle 1
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Primary endpoint: Minimal residual disease (MRD)-negativity rate
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse
Primary endpoint: Percentage of Participants With Complete Response (CR) Rate
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Primary endpoint: Event-free survival of ALL patients (EFS)
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Primary endpoint: Percentage of Participants with Adverse Events (AEs)